1. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.
- Author
-
Smith CA, Ng CY, Heslop HE, Holladay MS, Richardson S, Turner EV, Loftin SK, Li C, Brenner MK, and Rooney CM
- Subjects
- Adolescent, Adult, Cell Line, Transformed transplantation, Cell Transformation, Viral, Child, Child, Preschool, Female, Herpesviridae Infections virology, Herpesvirus 4, Human immunology, Humans, Immunophenotyping, Infant, Lymphoproliferative Disorders virology, Male, Middle Aged, Risk Factors, T-Lymphocytes, Cytotoxic immunology, Tumor Virus Infections prevention & control, Tumor Virus Infections virology, Bone Marrow Transplantation adverse effects, Herpesviridae Infections prevention & control, Herpesvirus 4, Human physiology, Immunotherapy, Adoptive methods, Lymphoproliferative Disorders prevention & control, T-Lymphocytes, Cytotoxic transplantation
- Abstract
EBV-induced lymphoproliferative disease (EBV-LPD) is a disorder most commonly associated with the immunocompromise that follows allogeneic organ transplantation. In patients receiving T cell-depleted bone marrow from HLA-mismatched or HLA-matched unrelated donors, the incidence of EBV-LPD is particularly high, ranging from 5 to 30%. Administration of EBV-specific cytotoxic T lymphocytes may be one means of preventing and treating this disease. We now describe a method that allows the routine and timely preparation of large numbers of such cells to allow their safe administration to bone marrow transplant recipients. We also describe how these cells may be genetically marked before infusion, to determine their fate and disposition in vivo.
- Published
- 1995
- Full Text
- View/download PDF